株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗体関連の各種提携契約 - 契約条件・合意内容 (2014~2019年):資本取引の動向・企業・財務状況

Global Antibody Partnering Terms and Agreements 2014-2019: Deal trends, players and financials

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 234470
出版日 ページ情報 英文 750+ Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.53円で換算しております。
Back to Top
抗体関連の各種提携契約 - 契約条件・合意内容 (2014~2019年):資本取引の動向・企業・財務状況 Global Antibody Partnering Terms and Agreements 2014-2019: Deal trends, players and financials
出版日: 2019年11月01日 ページ情報: 英文 750+ Pages
概要

当レポートでは、抗体関連の各種資本取引/事業提携の契約締結について分析し、近年における各種契約の締結動向や、大規模契約および大手医薬品事業者による契約の概要、契約種類別/治験段階別/技術別/治療内容別の契約一覧、といった情報を取りまとめてお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 抗体関連の各種取引動向

  • イントロダクション
  • 近年の抗体関連の事業提携件数
  • 最も活動的だった、抗体関連の取引主体
  • 抗体関連の事業提携:取引の種類別
  • 抗体関連の事業提携:治療領域別
  • 抗体関連の事業提携:取引条件
    • 取引総額 (headline values)
    • 前払い金
    • マイルストーン払い
    • ロイヤルティ率

第3章 抗体関連の主要な取引

  • イントロダクション
  • 代表的な資本取引 - 取引金額

第4章 抗体関連の最も活動的な取引主体

  • イントロダクション
  • 抗体関連の最も活動的な取引主体
  • 最も活動的な取引主体:企業プロファイル

第5章 抗体関連の契約締結の一覧

  • イントロダクション
  • 締結された契約の一覧 (ディレクトリ)

第6章 抗体関連の取引動向:技術の種類別

第7章 抗体関連のリソースセンター

  • 抗体関連のオンライン・データベース
  • 抗体関連のイベント/会議
  • 抗体関連の参考文献

付録

  • 付録 (1) - 抗体関連の資本取引:企業別 (ABC順)
  • 付録 (2) - 抗体関連の資本取引:治験段階別
    • 創薬
    • 前臨床
    • 第I相
    • 第II相
    • 第III相
    • 申請登録
    • 上市済み
    • 剤型
  • 付録 (3) - 抗体関連の資本取引:取引の種類別
    • 資産購入
    • 権利譲渡
    • 大手医薬品企業のアウトライセンシング
    • 共同開発
    • 共同研究開発 (R&D)
    • 共同マーケティング
    • 共同プロモーション
    • CRADA (共同研究開発契約)
    • クロスライセンシング
    • 開発
    • 流通
    • 株式購入
    • 評価
    • 譲与
    • 合弁事業 (ジョイントベンチャー)
    • ライセンシング
    • ローン
    • 製造
    • マーケティング
    • 材料転移
    • オプション
    • プロモーション
    • 研究
    • 和解調停
    • スピンアウト
    • 二次ライセンス
    • 供給
    • 技術移転
    • 契約解除
  • 付録 (4) - 抗体関連の資本取引:治療領域別
    • 心血管
    • 中枢神経系
    • 歯科
    • 皮膚科
    • 消化器
    • 血液
    • 入院治療
    • 免疫
    • 感染症
    • 代謝
    • 筋骨格系疾患
    • 産科
    • 腫瘍 (癌)
    • 眼科
    • 希少疾患
    • 小児科
    • 精神科
    • 呼吸器
  • 付録 (5) - 資本取引の種類:定義

Wildwood Venturesについて

目次
Product Code: CP2113

The ‘Global Antibody Partnering Terms and Agreements 2014-2019’ report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies

The ‘Global Antibody Partnering Terms and Agreements 2014 to 2019’ report provides comprehensive understanding and unprecedented access to the Antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:

  • Antibodies
  • Antibody-drug conjugates
  • Monoclonal antibodies
  • Murine mAb
  • Chimeric mAb
  • Humanized mAb
  • Human aAb
  • Polyclonal Antibodies

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 1,100 links to online copies of actual Antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of Antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Antibody dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Antibody deals since 2014. Deals are listed by headline value, signed by big pharma, most active Antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Antibody dealmaking with a brief summary followed by a comprehensive listing of Antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan to 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Antibody partnering deals signed and announced since Jan to 2014. The chapter is organized by specific Antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Antibody partnering company A-Z, deal type definitions and Antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Antibody partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Antibody technologies and products.

Key benefits

‘Global Antibody Partnering Terms and Agreements 2014 to 2019’ provides the reader with the following key benefits:

  • In-depth understanding of Antibody deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of Antibody agreements with real life case studies
  • Detailed access to actual Antibody contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a Antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Antibody Partnering Terms and Agreements 2014 to 2019’ is intended to provide the reader with an in-depth understanding and access to Antibody trends and structure of deals entered into by leading companies worldwide.

‘Global Antibody Partnering Terms and Agreements 2014 to 2019’ includes:

  • Trends in Antibody dealmaking in the biopharma industry since 2014
  • Analysis of Antibody deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life Antibody deals
  • Access to over 1,100 Antibody online deal records
  • The leading Antibody deals by value since 2014
  • Most active Antibody dealmakers since 2014
  • The leading Antibody partnering resources

In ‘Global Antibody Partnering Terms and Agreements 2014 to 2019’, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Antibody Partnering Terms and Agreements 2014 to 2019’ report provides comprehensive access to available deals and contract documents for over 1,100 Antibody deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise Antibody rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Antibody Partnering 2014-2019’ provides the reader with the following key benefits:

  • In-depth understanding of antibody deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of antibody agreements with numerous real life case studies
  • Comprehensive access to over 1,100 actual antibody deals entered into by the world's biopharma companies, together with contract documents if available
  • Detailed access to actual antibody contracts enter into by the leading companies
  • Identify leading antibody deals by value since 2014
  • Identify the most active antibody dealmakers since 2014
  • Insight into the terms included in a antibody agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

  • 2.1. Introduction
  • 2.2. Antibody partnering over the years
  • 2.3. Most active antibody dealmakers
  • 2.4. Antibody partnering by deal type
  • 2.5. Antibody partnering by therapy area
  • 2.6. Deal terms for antibody partnering
    • 2.6.1 Antibody partnering headline values
    • 2.6.2 Antibody deal upfront payments
    • 2.6.3 Antibody deal milestone payments
    • 2.6.4 Antibody royalty rates

Chapter 3 - Leading antibody deals

  • 3.1. Introduction
  • 3.2. Top antibody deals by value

Chapter 4 - Most active antibody dealmakers

  • 4.1. Introduction
  • 4.2. Most active antibody dealmakers
  • 4.3. Most active antibody partnering company profiles

Chapter 5 - Antibody contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Antibody contracts dealmaking directory

Chapter 6 - Antibody dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Antibody deals by company A-Z
  • Appendix 2 - Antibody deals by stage of development
    • Discovery
    • Preclinical
    • Phase I
    • Phase II
    • Phase III
    • Regulatory
    • Marketed
    • Formulation
  • Appendix 3 - Antibody deals by deal type
    • Asset purchase
    • Assignment
    • Bigpharma outlicensing
    • Co-development
    • Collaborative R&D
    • Co-market
    • Co-promotion
    • CRADA
    • Cross-licensing
    • Development
    • Distribution
    • Equity purchase
    • Evaluation
    • Grant
    • Joint venture
    • Licensing
    • Loan
    • Manufacturing
    • Marketing
    • Material transfer
    • Option
    • Promotion
    • Research
    • Settlement
    • Spin out
    • Sub-license
    • Supply
    • Technology transfer
    • Termination
  • Appendix 4 - Antibody deals by therapy area
    • Cardiovascular
    • Central Nervous System
    • Dental
    • Dermatology
    • Gastrointestinal
    • Hematology
    • Hospital care
    • Immunology
    • Infectives
    • Metabolic
    • Musculoskeletal
    • Obstetrics
    • Oncology
    • Ophthalmics
    • Orphan disease
    • Pediatrics
    • Psychiatry
    • Respiratory
  • Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Therapeutic antibody definitions
  • Figure 2: Antibody partnering since 2014
  • Figure 3: Active antibody dealmaking activity since 2014
  • Figure 4: Antibody partnering by deal type since 2014
  • Figure 5: Antibody partnering by disease type since 2014
  • Figure 6: Antibody deals with a headline value
  • Figure 7: Antibody deals with an upfront value
  • Figure 8: Antibody deals with a milestone value
  • Figure 9: Antibody deals with a royalty rate value
  • Figure 10: Top antibody deals by value since 2014
  • Figure 11: Most active antibody dealmakers since 2014
  • Figure 12: Online partnering resources
  • Figure 13: Forthcoming partnering events
Back to Top